<DOC>
	<DOCNO>NCT01651325</DOCNO>
	<brief_summary>The purpose study assess effect multiple dose isavuconazole pharmacokinetics single dose dextromethorphan healthy adult subject .</brief_summary>
	<brief_title>Drug Interaction Study Multiple Doses Isavuconazole Single Dose Dextromethorphan Healthy Adult Subjects</brief_title>
	<detailed_description>Subjects check-in Day -1 remain confined clinical unit Day 13 . On morning Day 1 , subject receive single dose dextromethorphan . On Days 6 7 , subject receive isavuconazole three time daily ( TID ) administer approximately 8 hour apart . On Day 8 12 , subject receive isavuconazole daily ( QD ) . On Day 10 , subject receive single dose dextromethorphan . A follow-up visit schedule Day 21 ( ± 2 day ) .</detailed_description>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>The subject body weight least 45.0 kg body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive The subject 's 12lead electrocardiogram ( ECG ) normal Screening Day 1 , abnormal , abnormality clinically significant determine investigator , include QTcF 430 msec less male 450 msec less female subject The subject 's clinical laboratory test result Screening Day 1 within normal limit unless investigator considers abnormality clinically significant . Results aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) must ≤ upper limit normal , total bilirubin must ≤ 1.5 mg/dL The female subject agree sexual abstinence , surgically sterile , postmenopausal ( define least 2 year Screening without menses ) , use medically acceptable double barrier method ( e.g . spermicide diaphragm , spermicide condom ) prevent pregnancy agree continue use method Screening 3 week followup visit end study ; lactate pregnant document negative pregnancy test Screening Day 1 The male subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy agree continue use method Screening 3 week followup visit end study The subject clinically significant ( judged Investigator ) disease history follow system : pulmonary , gastrointestinal , cardiovascular ( include history clinically significant arrhythmia clinically significant conduction delay ECG ) , hepatic , neurological , psychiatric , renal , genitourinary , endocrine , metabolic , dermatologic , immunologic , hematologic , malignancy exclude non melanoma skin cancer The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic check Day 1 The subject receive vaccination within last 30 day prior study drug administration plan receive vaccination study within 2 week last dose study drug The subject positive result hepatitis C antibodies hepatitis B surface antigen Screening know positive human immunodeficiency virus ( HIV ) The subject know suspect allergy component trial product include dextromethorphan azole class compound , history multiple and/or severe allergy drug food ( judge investigator ) , history severe anaphylactic reaction The subject smoke ( use tobacco nicotine containing product ) within 6 month prior Screening The subject treatment prescription drug complementary alternative medicine within 14 day prior Day 1 , overthecounter medication within 1 week prior Day 1 , exception occasional use acetaminophen 2 g/day The subject receive experimental agent within 30 day 5 halflives , whichever longer , prior Day 1 The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic checkin Day 1 The subject take part strenuous exercise within 3 day prior study drug administration The subject anticipate inability abstain caffeine alcohol use 48 hour prior clinical checkin Day 1 throughout duration study ; grapefruit , Seville oranges , star fruit , product contain item 72 hour prior clinic checkin Day 1 throughout duration study The subject recent history ( within last 2 year ) drug alcohol abuse , define investigator , positive drug and/or alcohol screen Screening Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>dextrorphan</keyword>
	<keyword>DXM</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>BAL4815</keyword>
</DOC>